Two Sigma Investments’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.64M Sell
99,143
-174,733
-64% -$10.2M ﹤0.01% 2044
2026
Q2
$15.9M Buy
273,876
+162,566
+146% +$8.83M 0.01% 1191
2026
Q1
$6.47M Hold
111,310
– – 0.01% 1765
2025
Q4
$5.14M Buy
111,310
+3,723
+3% +$167K 0.01% 1707
2025
Q3
$3.88M Buy
107,587
+20,025
+23% +$663K 0.01% 1654
2025
Q2
$2.85M Buy
+87,562
New +$2.87M 0.01% 1587
2023
Q2
– Sell
-238,398
Closed -$8.94M – 3207
2023
Q1
$8.94M Buy
238,398
+38,239
+19% +$1.62M 0.03% 633
2022
Q4
$9.6M Buy
+200,159
New +$7.85M 0.03% 572

Other funds holding PCVX

Two Sigma Investments's PCVX Position: Q3 2026 in Review

Two Sigma Investments reduced its Vaxcyte (PCVX) stake by 64% in Q3 2026, selling an estimated $10.2M and leaving 99,143 shares worth $5.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2044.

Two Sigma Investments first reported a position in PCVX in Q4 2022 and has held it in 8 quarters since. The position peaked at $15.9M in Q2 2026. 356 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Two Sigma Investments held 99,143 shares of Vaxcyte worth $5.64M as of Q3 2026.
  • Two Sigma Investments sold 174,733 Vaxcyte shares in Q3 2026, an estimated $10.2M.
  • Vaxcyte made up ﹤0.01% of Two Sigma Investments's portfolio in Q3 2026, its #2044 holding.
  • Two Sigma Investments first reported a position in Vaxcyte in Q4 2022 and has held it in 8 quarters since.
  • Two Sigma Investments's Vaxcyte position peaked at $15.9M in Q2 2026.
  • 356 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Two Sigma Investments's 13F filing for Q3 2026, filed 16 Nov 2026.